>
WHO African Region Mpox Bulletin #10 – 27 October 2024
WHO African Region Mpox Bulletin #10 – 27 October 2024
Latest Updates on the Mpox Outbreak in the African Region
Introduction
The World Health Organization (WHO) African Region continues to monitor the evolving mpox outbreak in the region. As of 27 October 2024, a total of 1,237 confirmed cases and 151 deaths have been reported from 19 countries in the region. The most affected countries are Nigeria, Ghana, and the Democratic Republic of Congo.
Outbreak Trends
The outbreak is currently showing signs of stabilization in some countries, while others are still experiencing an increase in cases. In Nigeria, the number of new cases has declined significantly in recent weeks. However, in Ghana and the Democratic Republic of Congo, the number of cases continues to rise.
Public Health Response
WHO is working closely with affected countries to support their response efforts. The organization is providing technical assistance on case management, surveillance, and infection prevention and control. WHO is also supporting countries in the procurement of vaccines and other essential supplies.
Case Management and Treatment
The case fatality rate for mpox in the African Region is currently 12.2%. Most cases are mild, but severe cases can occur, especially in people with weakened immune systems. Treatment for mpox is supportive and includes pain relievers, fluids, and antibiotics for secondary infections.
Prevention and Control
The best way to prevent mpox is to avoid contact with infected people or animals. Other preventive measures include practicing good hygiene, such as washing hands frequently and avoiding contact with contaminated materials. Vaccination against mpox is also available and is recommended for people at high risk of exposure to the virus.
Conclusion
The mpox outbreak in the African Region is a serious public health concern. WHO is working closely with affected countries to support their response efforts. The organization is also providing technical assistance and guidance on case management, surveillance, and infection prevention and control.